Limited Fusion Works Great. Less Morbidity, Happy Patients, and Same Durability

Disclosure(s):

Robert K. Eastlack, MD: Aclarion Inc: Advisor (Ongoing), Stock Shareholder (excluding mutual funds) (Ongoing); Aesculap: Royalty Recipient (Terminated, November 1, 2024); Amgen: Consultant (Ongoing); ATEC Spine: Stock Shareholder (excluding mutual funds) (Ongoing); Globus NuVasive: Consultant (Ongoing), Royalty Recipient (Ongoing), Stock Shareholder (excluding mutual funds) (Ongoing); J&J MedTech: Consultant (Ongoing); Kuros Biosciences: Consultant (Ongoing), Research Grant (Ongoing); Mainstay Medical: Consultant (Ongoing); Medtronic: Consultant (Ongoing); NEO: Consultant (Ongoing), Stock Shareholder (excluding mutual funds) (Ongoing); OnPoint Surgical: Advisor (Ongoing), Stock Options (Ongoing), Stock Shareholder (excluding mutual funds) (Ongoing); Osteocentric: Consultant (Ongoing), Royalty Recipient (Ongoing), Stock Shareholder (excluding mutual funds) (Ongoing); Sea Spine/Orthofix: Consultant (Ongoing), Grant/Research Support (Ongoing), Royalty Recipient (Ongoing), Stock Shareholder (excluding mutual funds) (Ongoing); SI Bone: Consultant (Ongoing), Research Grant (Ongoing), Royalty Recipient (Ongoing), Stock Shareholder (excluding mutual funds) (Ongoing); Silony: Consultant (Terminated, November 20, 2024); Spinal Elements: Consultant (Ongoing)